These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 3379369)

  • 1. Should cholesterol-lowering drugs be used routinely to treat moderate hypercholesterolemia in patients with serum cholesterol levels of 6.20 to 6.85 mmol/L (240 to 265 mg/dL). An affirmative view.
    Crouch MA
    J Fam Pract; 1988 Jun; 26(6):665-70. PubMed ID: 3379369
    [No Abstract]   [Full Text] [Related]  

  • 2. Should cholesterol-lowering drugs be used routinely to treat moderate hypercholesterolemia in patients with serum cholesterol levels of 6.20 to 6.85 mmol/L (240 to 265 mg/dL). An opposing view.
    Zweig S
    J Fam Pract; 1988 Jun; 26(6):670-5. PubMed ID: 3132527
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cholesterol: how and when to treat it?].
    Masana Marín L
    Med Clin (Barc); 1985 Oct; 85(10):423-5. PubMed ID: 4079497
    [No Abstract]   [Full Text] [Related]  

  • 4. [Statins in primary prevention of coronary heart disease].
    Paulweber B
    Wien Med Wochenschr; 1999; 149(5-6):129-38. PubMed ID: 10408004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estimating cholesterol treatment rates among individuals with multiple risk factors and without coronary heart disease.
    Nag SS; Pearson TA; Ma L; Landsman PB; Cimino A; Vickers FF; Alexander CM; Melin JM
    Am J Cardiol; 2005 Apr; 95(7):862-4. PubMed ID: 15781017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The role of cholesterol-lowering drugs in prevention of coronary heart disease].
    Skałuba Z; Undas R
    Przegl Lek; 1998; 55(7-8):382-7. PubMed ID: 10021881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of pravastatin on coronary events in 2073 patients with low levels of both low-density lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study.
    Colquhoun D; Keech A; Hunt D; Marschner I; Simes J; Glasziou P; White H; Barter P; Tonkin A;
    Eur Heart J; 2004 May; 25(9):771-7. PubMed ID: 15120888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The management of hypercholesterolemia revisited.
    Wiggins BS
    Manag Care Interface; 2001 Jan; 14(1):58-66, 72. PubMed ID: 11214536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-molecular-weight hydroxypropylmethylcellulose. A cholesterol-lowering agent.
    Dressman JB; Adair CH; Barnett JL; Berardi RR; Dunn-Kucharski VA; Jarvenpaa KM; Parr DD; Sowle CA; Swidan SZ; Tobey SW
    Arch Intern Med; 1993 Jun; 153(11):1345-53. PubMed ID: 8507125
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The 10-minute consultation: accidently discovered hypercholesteremia].
    Tatò F
    MMW Fortschr Med; 2004 Sep; 146(35-36):59-60. PubMed ID: 15540545
    [No Abstract]   [Full Text] [Related]  

  • 11. High blood cholesterol.
    National Heart, Lung and Blood Institute
    Nutr Clin Care; 2003; 6(3):108-14. PubMed ID: 14979453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attaining United States and European guideline LDL-cholesterol levels with simvastatin in patients with coronary heart disease (the GOALLS study).
    Garmendia F; Brown AS; Reiber I; Adams PC
    Curr Med Res Opin; 2000; 16(3):208-19. PubMed ID: 11191012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction: missing the target with lipid-lowering therapy.
    Hunninghake DB; McKenney JM
    Am J Manag Care; 2000 Nov; 6(19 Suppl):S992-6. PubMed ID: 11187370
    [No Abstract]   [Full Text] [Related]  

  • 14. Lipoproteins and coronary heart disease.
    Krauss RM
    Postgrad Med; 1989 Apr; Spec No():54-8; discussion 89-90. PubMed ID: 2726627
    [No Abstract]   [Full Text] [Related]  

  • 15. LDL cholesterol lowering by bile acid malabsorption during inhibited synthesis and absorption of cholesterol in hypercholesterolemic coronary subjects.
    Gylling H; Miettinen TA
    Nutr Metab Cardiovasc Dis; 2002 Feb; 12(1):19-23. PubMed ID: 12125225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
    McKenney JM; Jones PH; Adamczyk MA; Cain VA; Bryzinski BS; Blasetto JW;
    Curr Med Res Opin; 2003; 19(8):689-98. PubMed ID: 14687438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ezetimibe treatment of pediatric patients with hypercholesterolemia.
    Clauss S; Wai KM; Kavey RE; Kuehl K
    J Pediatr; 2009 Jun; 154(6):869-72. PubMed ID: 19230898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving the prediction of cardiovascular risk: interaction between LDL and HDL cholesterol.
    Grover SA; Dorais M; Coupal L
    Epidemiology; 2003 May; 14(3):315-20. PubMed ID: 12859032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical appraisal of revised cholesterol guidelines for the very high-risk patient.
    Rosenson R; Lloyd-Jones D;
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):173-8. PubMed ID: 15739256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.